219 related articles for article (PubMed ID: 35851311)
1. Structural insights into engineering a T-cell receptor targeting MAGE-A10 with higher affinity and specificity for cancer immunotherapy.
Simister PC; Border EC; Vieira JF; Pumphrey NJ
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35851311
[TBL] [Abstract][Full Text] [Related]
2. T cell receptor interactions with human leukocyte antigen govern indirect peptide selectivity for the cancer testis antigen MAGE-A4.
Coles CH; McMurran C; Lloyd A; Hock M; Hibbert L; Raman MCC; Hayes C; Lupardus P; Cole DK; Harper S
J Biol Chem; 2020 Aug; 295(33):11486-11494. PubMed ID: 32532817
[TBL] [Abstract][Full Text] [Related]
3. A TCR targeting the HLA-A*0201-restricted epitope of MAGE-A3 recognizes multiple epitopes of the MAGE-A antigen superfamily in several types of cancer.
Chinnasamy N; Wargo JA; Yu Z; Rao M; Frankel TL; Riley JP; Hong JJ; Parkhurst MR; Feldman SA; Schrump DS; Restifo NP; Robbins PF; Rosenberg SA; Morgan RA
J Immunol; 2011 Jan; 186(2):685-96. PubMed ID: 21149604
[TBL] [Abstract][Full Text] [Related]
4. Conserved Vδ1 Binding Geometry in a Setting of Locus-Disparate pHLA Recognition by δ/αβ T Cell Receptors (TCRs): Insight into Recognition of HIV Peptides by TCRs.
Shi Y; Kawana-Tachikawa A; Gao F; Qi J; Liu C; Gao J; Cheng H; Ueno T; Iwamoto A; Gao GF
J Virol; 2017 Sep; 91(17):. PubMed ID: 28615212
[TBL] [Abstract][Full Text] [Related]
5. CD8 T cell function and cross-reactivity explored by stepwise increased peptide-HLA versus TCR affinity.
Baumgaertner P; Schmidt J; Costa-Nunes CM; Bordry N; Guillaume P; Luescher I; Speiser DE; Rufer N; Hebeisen M
Front Immunol; 2022; 13():973986. PubMed ID: 36032094
[TBL] [Abstract][Full Text] [Related]
6. Phase I clinical trial evaluating the safety and efficacy of ADP-A2M10 SPEAR T cells in patients with MAGE-A10
Blumenschein GR; Devarakonda S; Johnson M; Moreno V; Gainor J; Edelman MJ; Heymach JV; Govindan R; Bachier C; Doger de Spéville B; Frigault MJ; Olszanski AJ; Lam VK; Hyland N; Navenot JM; Fayngerts S; Wolchinsky Z; Broad R; Batrakou D; Pentony MM; Sanderson JP; Gerry A; Marks D; Bai J; Holdich T; Norry E; Fracasso PM
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35086946
[TBL] [Abstract][Full Text] [Related]
7. Specificity of bispecific T cell receptors and antibodies targeting peptide-HLA.
Holland CJ; Crean RM; Pentier JM; de Wet B; Lloyd A; Srikannathasan V; Lissin N; Lloyd KA; Blicher TH; Conroy PJ; Hock M; Pengelly RJ; Spinner TE; Cameron B; Potter EA; Jeyanthan A; Molloy PE; Sami M; Aleksic M; Liddy N; Robinson RA; Harper S; Lepore M; Pudney CR; van der Kamp MW; Rizkallah PJ; Jakobsen BK; Vuidepot A; Cole DK
J Clin Invest; 2020 May; 130(5):2673-2688. PubMed ID: 32310221
[TBL] [Abstract][Full Text] [Related]
8. Direct molecular mimicry enables off-target cardiovascular toxicity by an enhanced affinity TCR designed for cancer immunotherapy.
Raman MC; Rizkallah PJ; Simmons R; Donnellan Z; Dukes J; Bossi G; Le Provost GS; Todorov P; Baston E; Hickman E; Mahon T; Hassan N; Vuidepot A; Sami M; Cole DK; Jakobsen BK
Sci Rep; 2016 Jan; 6():18851. PubMed ID: 26758806
[TBL] [Abstract][Full Text] [Related]
9. Molecular Rules Underpinning Enhanced Affinity Binding of Human T Cell Receptors Engineered for Immunotherapy.
Crean RM; MacLachlan BJ; Madura F; Whalley T; Rizkallah PJ; Holland CJ; McMurran C; Harper S; Godkin A; Sewell AK; Pudney CR; van der Kamp MW; Cole DK
Mol Ther Oncolytics; 2020 Sep; 18():443-456. PubMed ID: 32913893
[TBL] [Abstract][Full Text] [Related]
10. Affinity-enhanced T-cell receptors for adoptive T-cell therapy targeting MAGE-A10: strategy for selection of an optimal candidate.
Border EC; Sanderson JP; Weissensteiner T; Gerry AB; Pumphrey NJ
Oncoimmunology; 2019; 8(2):e1532759. PubMed ID: 30713784
[TBL] [Abstract][Full Text] [Related]
11. TCR gene transfer: MAGE-C2/HLA-A2 and MAGE-A3/HLA-DP4 epitopes as melanoma-specific immune targets.
Straetemans T; van Brakel M; van Steenbergen S; Broertjes M; Drexhage J; Hegmans J; Lambrecht BN; Lamers C; van Der Bruggen P; Coulie PG; Debets R
Clin Dev Immunol; 2012; 2012():586314. PubMed ID: 22400038
[TBL] [Abstract][Full Text] [Related]
12. Phase 1 Clinical Trial Evaluating the Safety and Anti-Tumor Activity of ADP-A2M10 SPEAR T-Cells in Patients With MAGE-A10+ Head and Neck, Melanoma, or Urothelial Tumors.
Hong DS; Butler MO; Pachynski RK; Sullivan R; Kebriaei P; Boross-Harmer S; Ghobadi A; Frigault MJ; Dumbrava EE; Sauer A; Brophy F; Navenot JM; Fayngerts S; Wolchinsky Z; Broad R; Batrakou DG; Wang R; Solis LM; Duose DY; Sanderson JP; Gerry AB; Marks D; Bai J; Norry E; Fracasso PM
Front Oncol; 2022; 12():818679. PubMed ID: 35372008
[TBL] [Abstract][Full Text] [Related]
13. Selection of a Clinical Lead TCR Targeting Alpha-Fetoprotein-Positive Liver Cancer Based on a Balance of Risk and Benefit.
Luo X; Cui H; Cai L; Zhu W; Yang WC; Patrick M; Zhu S; Huang J; Yao X; Yao Y; He Y; Ji Y
Front Immunol; 2020; 11():623. PubMed ID: 32425926
[TBL] [Abstract][Full Text] [Related]
14. High-throughput T cell receptor engineering by functional screening identifies candidates with enhanced potency and specificity.
Vazquez-Lombardi R; Jung JS; Schlatter FS; Mei A; Mantuano NR; Bieberich F; Hong KL; Kucharczyk J; Kapetanovic E; Aznauryan E; Weber CR; Zippelius A; Läubli H; Reddy ST
Immunity; 2022 Oct; 55(10):1953-1966.e10. PubMed ID: 36174557
[TBL] [Abstract][Full Text] [Related]
15. Selection, engineering, and in vivo testing of a human leukocyte antigen-independent T-cell receptor recognizing human mesothelin.
Hiscox MJ; Wasmuth A; Williams CL; Foot JN; Wiedermann GE; Fadda V; Boiani S; Cornforth TV; Wikiert KA; Bruton S; Cartwright N; Anderson VE; Barnes CS; Vieira JV; Birch-Machin I; Gerry AB; Miller K; Pumphrey NJ
PLoS One; 2024; 19(4):e0301175. PubMed ID: 38574067
[TBL] [Abstract][Full Text] [Related]
16. Preclinical Studies of the Off-Target Reactivity of AFP
Cai L; Caraballo Galva LD; Peng Y; Luo X; Zhu W; Yao Y; Ji Y; He Y
Front Immunol; 2020; 11():607. PubMed ID: 32395117
[TBL] [Abstract][Full Text] [Related]
17. Sulfamethoxazole induces a switch mechanism in T cell receptors containing TCRVβ20-1, altering pHLA recognition.
Watkins S; Pichler WJ
PLoS One; 2013; 8(10):e76211. PubMed ID: 24116097
[TBL] [Abstract][Full Text] [Related]
18. Optimization of T-cell Reactivity by Exploiting TCR Chain Centricity for the Purpose of Safe and Effective Antitumor TCR Gene Therapy.
Ochi T; Nakatsugawa M; Chamoto K; Tanaka S; Yamashita Y; Guo T; Fujiwara H; Yasukawa M; Butler MO; Hirano N
Cancer Immunol Res; 2015 Sep; 3(9):1070-81. PubMed ID: 25943533
[TBL] [Abstract][Full Text] [Related]
19. Isolation and Characterization of an HLA-DPB1*04: 01-restricted MAGE-A3 T-Cell Receptor for Cancer Immunotherapy.
Yao X; Lu YC; Parker LL; Li YF; El-Gamil M; Black MA; Xu H; Feldman SA; van der Bruggen P; Rosenberg SA; Robbins PF
J Immunother; 2016 Jun; 39(5):191-201. PubMed ID: 27163739
[TBL] [Abstract][Full Text] [Related]
20. Engineering Cancer Antigen-Specific T Cells to Overcome the Immunosuppressive Effects of TGF-β.
Silk JD; Abbott RJM; Adams KJ; Bennett AD; Brett S; Cornforth TV; Crossland KL; Figueroa DJ; Jing J; O'Connor C; Pachnio A; Patasic L; Peredo CE; Quattrini A; Quinn LL; Rust AG; Saini M; Sanderson JP; Steiner D; Tavano B; Viswanathan P; Wiedermann GE; Wong R; Jakobsen BK; Britten CM; Gerry AB; Brewer JE
J Immunol; 2022 Jan; 208(1):169-180. PubMed ID: 34853077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
